Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2020-04-22 Report Publication Anno…
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech Holding ASA publishes the Annual Report 2019
Report Publication Announcement Classification · 100% confidence The document explicitly states: "PCI Biotech Holding ASA publishes the Annual Report 2019" and "The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2019 and the report is attached." Although the content relates to the Annual Report 2019, the document itself is a short announcement (2974 characters) whose primary function is to state that the report has been published and is attached/available, rather than being the full, detailed 10-K filing. According to Rule 2, when a document is short and announces the publication of a report, it should be classified as a Report Publication Announcement (RPA).
2020-04-22 English
PCI Biotech appoints Dr Amir Snapir as Chief Medical Officer
Board/Management Information Classification · 99% confidence The document is a press release announcing the appointment of a new Chief Medical Officer (CMO), Dr. Amir Snapir, effective May 1, 2020. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The filing code for this category is MANG.
2020-03-31 English
PCI Biotech: US patent for the vaccine technology (fimaVacc) with a new important class of adjuvants
Regulatory Filings Classification · 100% confidence The document is a press release dated March 26, 2020, announcing that the USPTO will grant a new US patent covering the combination of the company's fimaVacc technology with TLR agonists. It discusses intellectual property, patent coverage until 2035, and future partnering efforts. This type of announcement, focusing on intellectual property protection (patents) and its strategic implications, does not fit neatly into the primary financial reporting categories (10-K, IR, ER, MRQ). While it relates to corporate activity, it is most closely aligned with general corporate news or regulatory updates concerning IP. Since it is a specific announcement about a patent grant, and not a general regulatory filing fallback (RNS), the closest fit among the provided options that covers specific corporate developments outside of core financials or governance is often categorized under general regulatory/corporate news. However, given the focus on intellectual property and its strategic value, it is a specific corporate announcement. Since there is no dedicated 'Intellectual Property' or 'Patent Announcement' code, and it is not a standard financial report, management change, or capital event, it defaults best to the general 'Regulatory Filings' (RNS) category as a significant, non-financial, mandatory disclosure, or potentially 'LTR' if viewed as a legal/IP matter, but RNS is the broader catch-all for significant non-standard announcements. Given the context of a press release announcing a patent grant, RNS is the most appropriate fallback for a specific corporate event not covered elsewhere.
2020-03-26 English
PCI Biotech: Update on operational implications of the corona pandemic
Regulatory Filings Classification · 99% confidence The document is titled "PCI Biotech: Update on operational implications of the corona pandemic" and provides a status update regarding clinical trials (RELEASE study), business development activities, and financial position in response to the COVID-19 pandemic. It is a specific, timely announcement concerning business operations and regulatory progress, rather than a comprehensive annual report (10-K), a formal earnings release (ER) focusing only on preliminary figures, or a transcript (CT). Since it is a specific operational update that doesn't fit neatly into the primary financial report categories (10-K, IR, ER), and it is not a standard regulatory filing like a Director's Dealing (DIRS) or Major Shareholding (MRQ), it best fits the general Regulatory Filings (RNS) category, which serves as a fallback for specific, non-standard operational or event disclosures required by securities regulations (as indicated by the final line referencing the Norwegian Securities Trading Act). Given the content is a direct operational update, it is not an announcement *about* a report (RPA).
2020-03-25 English
PCI Biotech's fourth quarter and preliminary 2019 results
Earnings Release Classification · 95% confidence The document is a presentation slide deck containing financial highlights for Q4 and Full Year 2019, dated February 26, 2020. It includes sections on Q4 highlights, clinical trial progress (fimaCHEM and fimaVACC), research collaborations, and key financial figures for Q4 2019 and FY 2019 compared to 2018. The presence of detailed financial tables (Operating results, Net change cash) and performance updates strongly suggests this is related to periodic financial reporting. Since it covers the full year (FY 2019) and the fourth quarter (Q4 2019), it is either an Annual Report (10-K) or an Interim/Quarterly Report (IR). Given the comprehensive nature covering the full fiscal year performance and the structure typical of investor updates following year-end results, it is most likely associated with the Annual Report cycle, even if it is a presentation summarizing the 10-K data. However, the content is structured as a presentation summarizing results, which often accompanies or precedes the formal 10-K filing. Since it explicitly covers 'Full Year 2019' results and financial tables, it aligns best with the comprehensive reporting associated with the Annual Report (10-K) or a detailed Investor Presentation (IP) summarizing those results. Because it contains detailed financial tables and full-year review, it is more substantial than a typical ER or MRQ. Given the context of a presentation summarizing the full year's performance, Investor Presentation (IP) is a strong candidate, but the inclusion of detailed financial statements (even summarized) often points towards the core reporting documents. Since it covers the full year and includes detailed financial performance metrics, it functions as the primary communication of the annual results, making 10-K the underlying context, but the format is an Investor Presentation. I will classify it as an Investor Presentation (IP) because it is explicitly titled a 'PRESENTATION' and details strategy and clinical progress alongside financials, which is the core function of an IP. Q4 2019
2020-02-26 English
PCI Biotech's fourth quarter and preliminary 2019 results
Investor Presentation Classification · 99% confidence The document explicitly states it is the "FOURTH QUARTER AND PRELIMINARY FULL YEAR REPORT 2019". This structure, covering a full fiscal year's performance along with the final quarter's results, strongly indicates an Annual Report or a comprehensive period report. While the content details financial tables (In NOK 1,000) and operational reviews typical of a 10-K, the specific title points towards a comprehensive annual filing. Since the document is a detailed report covering the full year and includes financial tables, it aligns best with the scope of an Annual Report (10-K) or a very detailed Interim/Quarterly Report (IR). Given the inclusion of 'FULL YEAR REPORT', 10-K is the most appropriate classification for a comprehensive annual filing, even if it might be an unfiled version or a press release version of the 10-K content. It is clearly not a short announcement (RPA/RNS) as the document length is substantial (81,883 chars) and contains full financial data and narrative review.
2020-02-26 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.